Votucalis, a Novel Centrally Sparing Histamine-Binding Protein, Attenuates Histaminergic Itch and Neuropathic Pain in Mice.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model (rodent study)
PubMed 35350753 · doi:10.3389/fphar.2022.846683
What was done
Adult male mice were subjected to models of histaminergic itch and peripheral nerve injury-induced neuropathic pain. Researchers evaluated the effects of Votucalis, a tick-derived high-affinity histamine-binding protein, administered either systemically (intraperitoneal) or peripherally (subcutaneous or intraplantar). Outcomes included itch behavior, mechanical hypersensitivity, and thermal hypersensitivity. Selective histamine receptor antagonists (H1, H2, and H4) were co-administered to examine receptor involvement, and the spontaneous object recognition test was conducted to evaluate centrally sparing properties.
What was found
The abstract reports no exact numerical values, effect sizes, or confidence intervals. Qualitatively, peripheral administration (subcutaneous or intraplantar) of Votucalis demonstrated a longer duration of action at a lower dose range compared to systemic intraperitoneal delivery. Co-administration of subcutaneous Votucalis with peripheral H1 and H2 receptor antagonists and central H4 receptor antagonists produced a stronger anti-itch effect. In neuropathic mice, Votucalis completely alleviated mechanical hypersensitivity but left thermal hypersensitivity largely unaffected. Spontaneous object recognition testing confirmed that Votucalis lacked central nervous system effects.
Why it matters
Scavenging peripheral histamine using a biologics-based approach provides proof-of-concept for attenuating histaminergic itch and neuropathic mechanical hypersensitivity without central nervous system penetration. This mechanism could offer a pathway for non-sedating treatments for refractory itch and neuropathic pain conditions.
Limits
The study was conducted entirely in male mice, limiting generalizability to females and humans. The abstract omits sample sizes, exact doses, numerical metrics, and statistical measures of variance. Potential immunogenicity or long-term safety issues associated with administering a foreign tick saliva protein were not addressed in the abstract.
Cited by
- supports Histamine and glutamate signaling pathways are directly involved in the cell signaling of chronic pain.